Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TNXP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTonix secures GPO agreement expanding TONMYA coverage to 17M commercially insured patients
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
New GPO agreement effective June 1, 2026 provides TONMYA coverage to approximately 17 million commercially insured individuals with standard utilization management criteria, significantly expanding market access beyond existing Medicaid.
Item 8.01 verify on EDGAR → -
medium
TONMYA already available under Medicaid in most states, covering approximately 75 million beneficiaries, establishing substantial baseline market access prior to this commercial expansion.
Item 8.01 verify on EDGAR →
Summary
Tonix Pharmaceuticals announced a significant commercial milestone for TONMYA, its fibromyalgia treatment, by securing a group purchasing organization agreement that extends coverage to approximately 17 million commercially insured patients effective June 1, 2026. This represents a major expansion beyond the product's existing Medicaid footprint of roughly 75 million beneficiaries across most states.
For retail investors, this GPO agreement is meaningful because it opens a new commercial insurance channel that could drive revenue growth. Commercial insurance typically offers higher reimbursement rates than Medicaid, potentially improving margins. The agreement includes standard utilization management criteria, suggesting mainstream acceptance of the product's clinical profile.
Investors should watch for upcoming quarterly earnings to assess whether this expanded coverage translates into prescription volume growth and revenue acceleration. The company's ability to convert this access into actual sales will be the key test of TONMYA's commercial viability in the competitive fibromyalgia market.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 8, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced it entered into an agreement with a group purchasing organization (“GPO”) that provides coverage for TONMYA®.
The company disclosed entering into an agreement with a group purchasing organization that provides coverage for TONMYA®. This expands commercial access and potential sales channels for the product through the GPO's member network.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 8, 2026, the Company announced it entered into an agreement with a GPO, effective June 1, 2026, that provides coverage to approximately 17 million U.S. commercially insured individuals, with standard utilization management criteria, for TONMYA.
Tonix entered into a Group Purchasing Organization (GPO) agreement that expands commercial insurance coverage for TONMYA to approximately 17 million individuals starting June 1, 2026. This represents a significant expansion of market access for the company's product beyond its existing Medicaid coverage.
Added in current filing · verify on EDGAR →
To date, TONMYA is available under Medicaid in most states, representing approximately 75 million Medicaid beneficiaries.
The company disclosed that TONMYA currently has Medicaid coverage in most states, providing access to approximately 75 million beneficiaries. This establishes the baseline market access context for the product prior to the new GPO agreement.
Event · Item 9.01 — Financial Statements and Exhibits
Tonix Pharmaceuticals filed an 8-K attaching a press release dated June 8, 2026; no material event details disclosed in the body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.01 Press Release of the Company, June 8, 2026
The 8-K references a press release dated June 8, 2026, but the body of the filing does not disclose the content or subject matter of that release. Without the exhibit text, the nature and materiality of the event cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify